https://www.selleckchem.com/products/oul232.html
Combining recent advances and controversies may help clarify our biological understanding of lung NENs and give practical information for the clinical decision-making process.We describe a case of coronavirus disease 2019 (COVID-19) in a patient with mixed cellularity classical Hodgkin lymphoma (cHL) undergoing brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) therapy. A 43-year-old man presented to our hospital with a complaint of fever, for which he was diagnosed with COVID-19 after a positive polymerase chain reac
Мне нравится
Комментарий
Перепост
